Spyre Therapeutics, Inc.
SYRE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.37 | -0.02 | 0.41 | 0.05 |
| FCF Yield | -2.96% | -5.12% | -4.21% | -3.40% |
| EV / EBITDA | -106.49 | -15.92 | -17.25 | -16.41 |
| Quality | ||||
| ROIC | -12.41% | -9.20% | -10.73% | -11.05% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 3.32 | 1.27 | 0.92 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 20.29% | -13.58% | -10.20% | -26.44% |
| Safety | ||||
| Net Debt / EBITDA | 5.80 | 1.57 | 0.91 | 1.46 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -14.83 | 0.00 | 0.00 | 0.00 |